Efficacy of a novel affitoxin targeting MOMP against Chlamydia trachomatis in vitro and in vivo

Targeted therapy is an attractive approach for treating infectious diseases. Affibody molecules have similar capability to Antibodies that facilitate molecular recognition in both diagnostic and therapeutic applications. Targeting major outer membrane protein (MOMP) for treating Infection of Chlamydia trachomatis, one of the most common sexually transmitted pathogens, is a promising therapeutic approach. Previously, we have reported a MOMP-specific affibody (ZMOMP:461) from phage display library. Here, we first fused it with modified Pseudomonas Exotoxin (PE38KDEL) and a cell-penetrating peptide (CPP) to develop an affitoxin, Z461X-CPP. We then verified the addition of both toxin and CPPs that did not affect the affinitive capability of ZMOMP:461 to MOMP. Upon uptake by C.trachomatis-infected cells, Z461X-CPP induced cell Apoptosis in vitro. In animal model, Z461X significantly shortened the duration of C. trachomatis Infection and prevented pathological damage in mouse reproductive system. These findings provide compelling evidence that the MOMP-specific affitoxin has great potential for targeting therapy of C. trachomatis Infection.

Chlamydia trachomatis; Affibody molecules; Affitoxin molecules; MOMP; targeted therapy.